atazanavir sulfate has been researched along with darunavir in 100 studies
| Studies (atazanavir sulfate) | Trials (atazanavir sulfate) | Recent Studies (post-2010) (atazanavir sulfate) | Studies (darunavir) | Trials (darunavir) | Recent Studies (post-2010) (darunavir) |
|---|---|---|---|---|---|
| 1,102 | 246 | 590 | 1,148 | 224 | 780 |
| Protein | Taxonomy | atazanavir sulfate (IC50) | darunavir (IC50) |
|---|---|---|---|
| Chain A, HIV-1 protease | Human immunodeficiency virus 1 | 0.0028 | |
| Chain B, HIV-1 protease | Human immunodeficiency virus 1 | 0.0028 | |
| Chain A, HIV-1 protease | Human immunodeficiency virus 1 | 0.0028 | |
| Chain B, HIV-1 protease | Human immunodeficiency virus 1 | 0.0028 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 6.6 | |
| Protease | Human immunodeficiency virus 1 | 0.063 | |
| Protease | Human immunodeficiency virus 1 | 0.0014 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (7.00) | 29.6817 |
| 2010's | 76 (76.00) | 24.3611 |
| 2020's | 17 (17.00) | 2.80 |
| Authors | Studies |
|---|---|
| De Marez, T; De Paepe, E; De Pauw, M; Hoetelmans, RM; Lefebvre, E; Sekar, VJ; Spinosa-Guzman, S; Vangeneugden, T | 1 |
| Adams, E; Hoogmartens, J; Van Schepdael, A; Yekkala, R | 1 |
| Louis, JM; Sayer, JM | 1 |
| Diego Miralles, G; Lefebvre, E; Sekar, V; Tomaka, F; Van Baelen, B; Vandevoorde, A; Vangeneugden, T | 1 |
| Sax, PE | 1 |
| Backus, LI; Belperio, PS; Boothroyd, DB; Mole, LX | 1 |
| Barreiro, P; Fernández-Montero, JV; Soriano, V | 1 |
| Backus, LI; Belperio, PS; Boothroyd, DB; Mole, LA | 1 |
| Carper, MJ; Lei, X; Ramanadham, S; Richmond, SR; Yarasheski, KE; Zhang, S | 1 |
| Fessel, WJ; Hellinger, J; Kaufman, D; Rhee, SY; Ruane, P; Shafer, RW; Shirvani, V; Taylor, J; Towner, W; Troia, P; Zolopa, A | 1 |
| de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Picchio, G; Spinosa-Guzman, S; Van De Casteele, T; Vanden Abeele, C | 1 |
| Amara, A; Back, D; Boffito, M; Gazzard, B; Higgs, C; Jackson, A; Khoo, S; Moyle, G; Seymour, N | 1 |
| Bower, M; Gazzard, B; Mandalia, S; Nelson, M; Rockwood, N | 1 |
| de Serres, M; Gould, E; Johnson, M; Kim, J; Lou, Y; Mayers, D; Pietropaolo, K; Piscitelli, S; White, S; Zhou, XJ | 1 |
| Auclair, M; Capeau, J; Capel, E; Caron-Debarle, M | 1 |
| Aberg, JA; De La Rosa, G; Falcon, R; Gupta, SK; Landay, A; Overton, ET; Ryan, R; Sax, PE; Tebas, P | 1 |
| Butterton, JR; Feng, HP; Hughes, EA; Hulskotte, EG; O'Mara, E; Treitel, MA; van Zutven, MG; Wagner, JA; Xuan, F; Youngberg, SP | 1 |
| Bandaranayake, RM; King, NM; Mittal, S; Nalam, MN; Nalivaika, EA; Prabu-Jeyabalan, M; Schiffer, CA; Yilmaz, NK | 1 |
| Amano, M; Aoki, M; Campbell, JR; Das, D; Ghosh, AK; Mitsuya, H; Rao, KV; Salcedo-Gómez, PM; Tojo, Y; Xu, CX | 1 |
| Almond, L; Back, D; Khoo, S; Kirov, A; Marzolini, C; Owen, A; Seden, K; Siccardi, M | 1 |
| Daudon, M; de Lastours, V; Ferrari Rafael De Silva, E; Loze, B; Molina, JM; Porcher, R; Sauvageon, H | 1 |
| Barreiro, P; Fernández-Montero, JV; Labarga, P; Soriano, V; Vispo, E | 1 |
| Bailey, JR; Chioma, S; Durand, CM; Laird, GM; Laskey, S; Moore, RD; Rabi, SA; Shan, L; Siliciano, RF | 1 |
| Guaraldi, G; Santoro, A; Stentarelli, C; Zona, S | 1 |
| Amano, M; Das, D; Ghosh, AK; Mitsuya, H; Mizuno, A; Salcedo Gómez, PM; Yashchuk, S | 1 |
| Gatanaga, H; Hamada, Y; Kikuchi, Y; Kinai, E; Komatsu, H; Nishijima, T; Oka, S; Teruya, K; Tsukada, K; Watanabe, K | 1 |
| Deeks, ED | 1 |
| Bernardino, JI; Carton, JA; Curran, A; Domingo, P; Ferrer, E; Gatell, JM; Gonzalez-Cordon, A; Gutierrez, F; Martinez, E; Murillas, J; Negredo, E; Peraire, J; Perez, I; Pich, J; Podzamczer, D; Portilla, J; Santos, I | 1 |
| Afonso, P; Auclair, M; Capeau, J; Capel, E; Caron-Debarle, M | 1 |
| Mishra, T; Shrivastav, PS | 1 |
| Fletcher, CV; Podany, AT; Robbins, BL; Winchester, LC | 1 |
| Castillero-Manzano, M; Escoto-Delgadillo, M; Flores-Soto, M; Gálvez-Gastelum, F; Mata-Munguía, C; Torres-Mendoza, B; Vázquez-Torres, M; Vázquez-Valls, E; Viniegra-Osorio, A | 1 |
| Acosta, EP; Armstrong, WS; Arrendale, RF; Delille, CA; Easley, KA; Lennox, JL; Marconi, VC; Ofotokun, I; Pruett, ST; Sheth, AN; Vunnava, A | 1 |
| Duan, J; Freeling, JP; Ho, RJ; Koehn, J; Shu, C | 1 |
| Aweeka, F; Baugh, BP; Benson, CA; Brown, TT; Cohn, SE; Currier, JS; Fichtenbaum, CJ; Godfrey, C; Haas, DW; Koletar, SL; Kuritzkes, DR; Landovitz, RJ; Leavitt, RY; Lennox, JL; McComsey, GA; Na, LH; Ofotokun, I; Patterson, KB; Presti, RM; Ribaudo, HJ; Rooney, JF; Sagar, M; Seekins, D | 1 |
| Bamford, A; Foster, C; James, M; Walters, S; Xiang, N | 1 |
| Minaeva, SV; Moshkovich, GF | 1 |
| Aweeka, F; Baugh, BP; Brown, TT; Cohn, SE; Currier, JS; Godfrey, C; Kuritzkes, DR; Landovitz, RJ; Leavitt, RY; Lennox, JL; McComsey, GA; Na, LH; Ofotokun, I; Para, MF; Patterson, KB; Ribaudo, HJ; Sagar, M; Villasis-Keever, A | 1 |
| Brown, TT; Currier, JS; Dube, MP; Kelesidis, T; McComsey, GA; Moser, C; Murphy, R; Ribaudo, HJ; Stein, JH; Tran, TT; Yang, OO | 1 |
| Brown, TT; Currier, JS; Dubé, MP; Kelesidis, T; McComsey, GA; Moser, C; Murphy, RL; Ribaudo, HJ; Rothenberg, J; Stein, JH; Yang, O | 1 |
| Brouillette, M; Farr, AM; Johnston, SS; Ritchings, C; Rosenblatt, L | 1 |
| Arribas, JR; Elbirt, D; Girard, PM; Hadacek, MB; Hill, A; Marcelin, AG; Paton, N; Winston, A | 1 |
| Aghokeng, AF; Bertagnolio, S; Carmona, S; Chua, A; De Oliveira, T; Fitzgibbon, JE; Fokam, J; Frenkel, LM; Gallant, JE; Gupta, RK; Hamers, RL; Hosseinipour, MC; Jordan, MR; Kantor, R; Katzenstein, D; Mukui, I; Ndembi, N; Parkin, N; Raizes, E; Rhee, SY; Richman, DD; Rinke de Wit, TF; Schapiro, JM; Schito, M; Shafer, RW; Tang, M; Van Zyl, GU; Wainberg, MA; Wallis, CL; Wensing, AM; Yang, C; Zeh, C | 1 |
| Baugh, BP; Coate, B; Dayaram, YK; De La Rosa, G; Overton, ET; Perniciaro, A; Ryan, R; Tebas, P | 1 |
| Back, D; Gibbons, S; Khoo, S; Marzolini, C | 1 |
| Assoumou, L; Benalycherif, A; Cabié, A; Costagliola, D; Duvivier, C; Girard, PM; Joly, V; Lambert-Niclot, S; Landman, R; Marcelin, AG; Peytavin, G; Pialoux, G; Samri, A; Slama, L; Valin, N | 1 |
| Cavadas, C; Costa, S; do Céu Sousa, M; Machado, M | 1 |
| Brown, TT; Currier, JS; Dube, MP; Kelesidis, T; McComsey, GA; Moser, C; Ribaudo, HJ; Stein, JH; Tran, TT; Yang, OO | 1 |
| Bonet, J; Bonjoch, A; Clotet, B; Echeverría, P; Juega, J; Negredo, E; Pérez-Alvarez, N; Puig, J; Romero, R | 1 |
| Brown, TT; Currier, JS; Dube, MP; Kelesidis, T; McComsey, GA; Moser, C; Ribaudo, HJ; Stein, JH; Tran, TTT; Yang, OO | 1 |
| Post, FA | 1 |
| Luetkehoelter, J; Tseng, AL; Walmsley, SL | 1 |
| Claiborne, DT; Collier, DA; Deymier, MJ; Goldstein, RA; Gupta, RK; Hunter, E; Prince, JL; Sutherland, KA | 1 |
| Cattaneo, D; Clementi, E; Cozzi, V; Galli, M; Gervasoni, C; Meraviglia, P; Minisci, D; Riva, A | 1 |
| Kaleebu, P; Kapaata, AA; Kasamba, I; Kazooba, P; Lutaakome, J; Lyagoba, F; Mayanja, BN; Munderi, P; Namakoola, I | 1 |
| Chadwick, D; Hamzah, L; Jones, R; Jose, S; Nelson, M; Phillips, A; Post, FA; Sabin, CA; Trevelion, R; Williams, DI | 1 |
| Arduino, G; Ariaudo, A; Bonora, S; Calcagno, A; Carcieri, C; D'Avolio, A; Di Perri, G; Marinaro, L; Pagani, N; Tettoni, MC; Trentini, L | 1 |
| Abdel-Maboud, M; Abushouk, AI; Ahmed, H; Attia, A; Elmaraezy, A; Gadelkarim, M; Ismail, A; Menshawy, A; Menshawy, E; Negida, A | 1 |
| Antoniou, T; Bayoumi, AM; Burchell, AN; Cooper, C; Hogg, RS; Klein, MB; Loutfy, M; Machouf, N; Montaner, JS; Raboud, J; Szadkowski, L; Tsoukas, C; Walmsley, S; Wong, A | 1 |
| Centeno-Tablante, E; Cotton, MF; Frigati, L; Lazarus, E; Nicol, L; Nicol, S; Penazzato, M; Violari, A | 1 |
| Amara, A; Boffito, M; Elliot, ER; Else, L; Higgs, C; Khoo, S; Moyle, G; Pagani, N; Schoolmeesters, A | 1 |
| Angarano, G; Bellacosa, C; Bellazzi, LI; Celesia, BM; Chirianni, A; Cicalini, S; Corsi, P; Grilli, E; Ladisa, N; Leone, A; Maggi, P; Martinelli, C; Maserati, R; Ricci, ED; Sozio, F; Viglietti, R; Volpe, A | 1 |
| Chatelut, E; Delobel, P; Gandia, P; Metsu, D; Toutain, PL | 1 |
| Hughes, CA; Phillips, EJ; Seet, J; Tseng, A; Wu, J | 1 |
| Abgrall, S; Arribas, JR; Barger, D; Barrufet, P; Braun, D; Caniglia, EC; Cardoso, SW; Chrysos, G; Costagliola, D; Gill, J; Gogos, C; Hauser, C; Hernán, MA; Hoyos, SP; Justice, A; Leyes, M; Lodi, S; Logan, R; Meyer, L; Moreno, S; Muga, R; Pacheco, A; Phillips, A; Porter, K; Reiss, P; Sabin, CA; Seng, R; Tate, J; van Sighem, A; Vandenhende, MA; Winston, A | 1 |
| Calvez, V; Charpentier, C; Descamps, D; Joly, V; Landman, R; Marcelin, AG; Perrier, M; Todesco, E; Visseaux, B; Yazdanpanah, Y | 1 |
| Chen, JS; DiMeglio, LA; Geffner, ME; Jacobson, D; Jao, J; Karalius, B; McFarland, EJ; Miller, TL; Mirza, A; Patel, K; Silio, M; Van Dyke, RB; Yu, W | 1 |
| Lundgren, J; Mocroft, A; Ryom, L | 1 |
| Cetin, I; Dalzero, S; Degli Antoni, A; Floridia, M; Francisci, D; Frisina, V; Liuzzi, G; Maccabruni, A; Masuelli, G; Ravizza, M; Sansone, M; Simonazzi, G; Tamburrini, E; Tassis, B | 1 |
| Cattaneo, D; Formenti, T; Fossati, A; Gervasoni, C; Meraviglia, P; Minisci, D; Resnati, C | 1 |
| d' Arminio Monforte, A; Dabis, F; De Wit, S; El-Sadr, W; Fontas, E; Hatleberg, CI; Kirk, O; Law, M; Lundgren, JD; Mocroft, A; Phillips, A; Reiss, P; Ryom, L; Sabin, C; Weber, R | 1 |
| Borghetti, A; Castelli, F; Izzo, I; Lombardi, F; Maggiolo, F; Magro, P; Quiros-Roldan, E; Raffetti, E; Saracino, A | 1 |
| Flaisigová, I; Günterová, J; Humpolíčková, J; Konvalinka, J; Majerová, T; Mašínová, E; Starková, J; Weber, J | 1 |
| Brogan, AJ; Davis, AE; Goodwin, B | 1 |
| Antinori, A; Carrara, S; Cozzi Lepri, A; D'arminio Monforte, A; Dentone, C; Di Biagio, A; Fenoglio, D; Filaci, G; Giacometti, A; Lichtner, M; Marchetti, G; Sighinolfi, L | 1 |
| Baldin, G; Belmonti, S; Borghetti, A; Ciccullo, A; De Luca, A; Di Giambenedetto, S; Emiliozzi, A; Gagliardini, R; Lamonica, S; Lombardi, F; Montagnani, F; Moschese, D; Visconti, E | 1 |
| Bai, F; Battisti, A; Bavaro, DF; Bezenchek, A; De Luca, A; Di Carlo, D; Di Giambenedetto, S; Gagliardini, R; Giachè, S; Incardona, F; Lo Caputo, S; Pecorari, M; Salomoni, E; Zazzi, M; Zuccalà, P | 1 |
| Butterton, JR; Caro, L; Chu, X; de Hoon, JN; De Lepeleire, I; Denef, JF; Du, L; Dunnington, K; Fandozzi, C; Feng, HP; Fraser, IP; Guo, Z; Hanley, WD; Huang, X; Iwamoto, M; Jumes, P; Marshall, WL; Martinho, M; Mitselos, A; Panebianco, D; Talaty, J; Valesky, R; Vandermeulen, C; Yeh, WW | 1 |
| Brunel, V; Malval, B; Massy, N | 1 |
| Atzori, C; Baldelli, S; Cattaneo, D; Cozzi, V; Filice, C; Fusi, M; Gervasoni, C; Micheli, V | 1 |
| Mejias, A; Peeples, ME; Ramilo, O; Teng, MN | 1 |
| Boccara, F; Costagliola, D; Cotte, L; de Castro, N; Duval, X; Duvivier, C; Grabar, S; Katlama, C; Lang, S; Mary-Krause, M; Partisani, M; Potard, V; Raffi, F; Ronot-Bregigeon, S; Simon, A; Tattevin, P; Weiss, L; Zucman, D | 1 |
| Siedner, MJ; Triant, VA | 1 |
| Das, M; Kearney, BP; Ling, KH; Majeed, SR; West, S | 1 |
| Cottrell, ML; Deeks, SG; Hatano, H; Hoh, R; Hunt, PW; Kashuba, ADM; Lee, SA; Liegler, TJ; Savic, RM; Somsouk, M; Stephenson, S; Telwatte, S; Yukl, S | 1 |
| Adrian, S; Beghetto, B; Erlandson, KM; Feng, H; Guaraldi, G; Lake, JE; Ligabue, G; Miao, H; Milic, J; Nardini, G; Roncaglia, E; Scherzinger, A | 1 |
| Chan, WW; Li, M; Zucker, SD | 1 |
| Cazzaniga, A; Galli, M; Maier, J; Rusconi, S; Scrimieri, R | 1 |
| Andersson, LM; Edén, A; Eriksen, J; Gisslén, M; Mellgren, Å; Nilsson, S; Thalme, A; Treutiger, CJ; Tyrberg, E | 1 |
| Dallocchio, RN; De Vito, A; Delogu, G; Dessì, A; Madeddu, G; Serra, PA | 1 |
| Hatleberg, CI; Ryom, L; Sabin, C | 1 |
| Chaudhary, NS; Funderburg, N; Irvin, MR; Kind, T; Overton, ET; Saag, MS; Shrestha, S; Wiener, HW; Willig, AL | 1 |
| Brummel, SS; Chadwick, EG; Huo, Y; Jacobson, DL; Jao, J; Kacanek, D; Kahlert, CR; Patel, K; Powis, KM; Seage, GR; Shiau, S; Sultan-Beyer, L; Williams, PL; Yee, LM; Zash, R | 1 |
| Campisi, J; Desprez, PY; Hughes, JB; Kuehnemann, C; Melov, S; Wiley, CD | 1 |
| Elhadad, H; Hien, NM; Huy, NT; Tam, DNH; Tran, L | 1 |
| Atkinson, H; Coghlan, H; Edgerton, J; Elsby, R; Hodgson, D; Outteridge, S | 1 |
| Bamford, A; Burger, DM; Bwakura-Dangarembizi, M; Chabala, C; Colbers, A; Denti, P; Doerholt, K; Gibb, DM; Griffiths, AL; Makumbi, S; McIlleron, HM; Monkiewicz, LN; Mulenga, V; Mumbiro, V; Musiime, V; Nangiya, J; Szubert, AJ; Waalewijn, H; Wasmann, RE; Wiesner, L | 1 |
11 review(s) available for atazanavir sulfate and darunavir
| Article | Year |
|---|---|
Quality control of protease inhibitors.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Chromatography, Liquid; Darunavir; Drug Contamination; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Organophosphates; Pyridines; Pyrimidinones; Pyrones; Quality Control; Ritonavir; Saquinavir; Sulfonamides | 2008 |
HIV protease inhibitors: recent clinical trials and recommendations on use.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Atazanavir Sulfate; Clinical Trials as Topic; Darunavir; Drug Interactions; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Metabolome; Oligopeptides; Pyridines; Pyrones; Sulfonamides; Treatment Outcome | 2009 |
HIV-associated lipodystrophy: impact of antiretroviral therapy.
Topics: Adiposity; Aging; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Darunavir; Drug Combinations; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Nucleosides; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Sulfonamides | 2013 |
Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection.
Topics: Atazanavir Sulfate; Carbamates; Cobicistat; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Synergism; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Pyridines; Sulfonamides; Thiazoles | 2014 |
Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials.
Topics: Atazanavir Sulfate; Cerebrospinal Fluid; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Treatment Outcome | 2016 |
Managing chronic kidney disease in the older adults living with HIV.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Chronic Disease; Darunavir; Drug Substitution; HIV Infections; Humans; Kidney; Kidney Diseases; Lopinavir; Middle Aged; Tenofovir | 2017 |
Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Darunavir; HIV Infections; HIV-1; Humans; Lopinavir; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2017 |
Second- and Third-line Antiretroviral Therapy for Children and Adolescents: A Scoping Review.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Cohort Studies; Darunavir; Drug Administration Schedule; Female; HIV Infections; Humans; Male; Nitriles; Practice Guidelines as Topic; Pyridazines; Pyrimidines; Raltegravir Potassium; Viral Load | 2017 |
Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Darunavir; Drug Interactions; HIV Infections; Humans; Quinolones; Ritonavir | 2017 |
Contemporary protease inhibitors and cardiovascular risk.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cardiovascular Diseases; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Risk Assessment; Ritonavir | 2018 |
Cardiovascular risks associated with protease inhibitors for the treatment of HIV.
Topics: Animals; Atazanavir Sulfate; Atherosclerosis; Cardiovascular Diseases; Darunavir; Dyslipidemias; Heart Disease Risk Factors; HIV Infections; HIV Protease Inhibitors; Humans; Randomized Controlled Trials as Topic | 2021 |
23 trial(s) available for atazanavir sulfate and darunavir
| Article | Year |
|---|---|
Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers.
Topics: Adolescent; Adult; Area Under Curve; Atazanavir Sulfate; Chromatography, Liquid; Cross-Over Studies; Darunavir; Dose-Response Relationship, Drug; Drug Interactions; Female; Half-Life; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Male; Middle Aged; Nausea; Oligopeptides; Pyridines; Sulfonamides; Tandem Mass Spectrometry; Time Factors; Vomiting | 2007 |
Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.
Topics: Adolescent; Adult; Atazanavir Sulfate; Blood Glucose; Darunavir; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fasting; HIV Protease Inhibitors; HIV Seronegativity; Humans; Insulin; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Sulfonamides; Triglycerides; Young Adult | 2009 |
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
Topics: Adamantane; Adult; Analysis of Variance; Atazanavir Sulfate; Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Microbial Sensitivity Tests; Molecular Typing; Nelfinavir; Neuraminidase; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides; Viral Load | 2010 |
Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation.
Topics: Adolescent; Adult; Aged; Atazanavir Sulfate; Darunavir; Female; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Sulfonamides; Young Adult | 2011 |
Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.
Topics: Adenine; Androstenes; Anti-HIV Agents; Atazanavir Sulfate; Atorvastatin; Contraceptives, Oral; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Interactions; Emtricitabine; Ethinyl Estradiol; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Least-Squares Analysis; Linear Models; Lopinavir; Male; Oligopeptides; Organophosphonates; Patient Safety; Phosphinic Acids; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tenofovir | 2012 |
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Atazanavir Sulfate; Biomarkers; CD4 Lymphocyte Count; Darunavir; Disease Progression; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Protease Inhibitors; HIV-1; Humans; Insulin Resistance; Lipids; Male; Middle Aged; Oligopeptides; Pilot Projects; Pyridines; Ritonavir; RNA, Viral; Sulfonamides; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2012 |
Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Darunavir; Dose-Response Relationship, Drug; Drug Interactions; Female; Hepacivirus; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Pyridines; Ritonavir; Sulfonamides; Young Adult | 2013 |
Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir.
Topics: Adult; Atazanavir Sulfate; Bilirubin; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Darunavir; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Lipids; Male; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; RNA, Viral; Spain; Sulfonamides | 2014 |
Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Blood Proteins; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Neopterin; Oligopeptides; Protein Binding; Pyridines; Ritonavir; RNA, Viral; Sulfonamides | 2014 |
[Initial HIV therapy. ACTG 5257: convincing results for raltegravir compared with protease inhibitors].
Topics: Acquired Immunodeficiency Syndrome; Atazanavir Sulfate; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Guideline Adherence; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2014 |
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
Topics: Adenine; Adult; Atazanavir Sulfate; Darunavir; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonamides; Tenofovir; Therapeutic Equivalency; Viral Load | 2014 |
[Results of a comparative study of the efficacy of once daily darunavir/atazanavir in treatment-naïve patients with HIV infection].
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Pyridines; Ritonavir; RNA, Viral; Sulfonamides; Time Factors; Viral Load | 2014 |
Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Blood Glucose; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Raltegravir Potassium; Ritonavir | 2015 |
Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biomarkers; Darunavir; Female; HIV Infections; Humans; Inflammation; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Raltegravir Potassium; Treatment Outcome | 2015 |
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bone Density; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Middle Aged; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load; Young Adult | 2015 |
Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Ritonavir; Viral Load; Young Adult | 2016 |
Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomiz
Topics: Adult; Africa; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nucleosides; Ritonavir; Treatment Outcome; Viral Load | 2016 |
Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carotid Intima-Media Thickness; Darunavir; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Linear Models; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Prospective Studies; Raltegravir Potassium; Ritonavir; RNA, Viral; Tenofovir | 2017 |
Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Darunavir; Female; Half-Life; Healthy Volunteers; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Saliva; Young Adult | 2017 |
Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cost-Benefit Analysis; Darunavir; Drug Therapy, Combination; Female; Health Care Costs; HIV Infections; HIV-1; Humans; Male; Models, Economic; Raltegravir Potassium; Ritonavir; United States | 2018 |
Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
Topics: Adult; Amides; Antiviral Agents; Atazanavir Sulfate; Benzofurans; Carbamates; Cyclopropanes; Darunavir; Drug Interactions; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Lopinavir; Male; Middle Aged; Quinoxalines; Ritonavir; Sulfonamides; Viral Nonstructural Proteins; Young Adult | 2019 |
Confirmation of the drug-drug interaction potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives.
Topics: Adolescent; Adult; Androstenes; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Cobicistat; Cohort Studies; Contraceptives, Oral, Hormonal; Darunavir; Drug Interactions; Ethinyl Estradiol; Female; Half-Life; Humans; Mineralocorticoid Receptor Antagonists; Young Adult | 2019 |
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Child; Darunavir; Emtricitabine; Fumarates; HIV Infections; Humans; Lopinavir; Protease Inhibitors; Ritonavir; Tenofovir | 2023 |
66 other study(ies) available for atazanavir sulfate and darunavir
| Article | Year |
|---|---|
Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
Topics: Atazanavir Sulfate; Binding Sites; Binding, Competitive; Calorimetry, Differential Scanning; Carbamates; Crystallography, X-Ray; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Kinetics; Lopinavir; Models, Molecular; Molecular Structure; Mutation; Nelfinavir; Oligopeptides; Pepsin A; Protein Binding; Protein Structure, Tertiary; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Saquinavir; Sulfonamides | 2009 |
Report from the 2008 joint ICAAC/IDSA meeting. Darunavir and atazanavir: 96-week data from ARTEMIS and CASTLE.
Topics: Atazanavir Sulfate; CD4 Lymphocyte Count; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines; Sulfonamides; Viral Load | 2008 |
Provider prescribing of 4 antiretroviral agents after implementation of drug use guidelines in the Department of Veterans Affairs.
Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Darunavir; Enfuvirtide; Guideline Adherence; Guidelines as Topic; Health Plan Implementation; HIV Envelope Protein gp41; HIV Infections; Humans; Oligopeptides; Peptide Fragments; Practice Patterns, Physicians'; Pyridines; Pyrones; Retrospective Studies; Sulfonamides; Time Factors; United States; United States Department of Veterans Affairs | 2009 |
Trends in uptake of recently approved antiretrovirals within a national healthcare system.
Topics: Ambulatory Care Facilities; Anti-Retroviral Agents; Atazanavir Sulfate; Cohort Studies; Darunavir; Drug Approval; Drug Prescriptions; Electronic Health Records; Female; Health Facility Size; HIV Infections; Humans; Male; Oligopeptides; Practice Patterns, Physicians'; Pyridines; Pyrones; Retrospective Studies; Sulfonamides; Time Factors; United States; United States Food and Drug Administration; Veterans | 2010 |
HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters.
Topics: Animals; Atazanavir Sulfate; Carnitine O-Palmitoyltransferase; CD36 Antigens; Cell Line; Darunavir; Dose-Response Relationship, Drug; Fatty Acid Transport Proteins; Fatty Acids; HIV Protease Inhibitors; Humans; Lopinavir; Mice; Muscle Fibers, Skeletal; Muscle, Skeletal; Oligopeptides; Oxidation-Reduction; Pyridines; Pyrimidinones; Ritonavir; Sulfonamides | 2010 |
HIV-1 protease mutations and protease inhibitor cross-resistance.
Topics: Atazanavir Sulfate; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Indinavir; Least-Squares Analysis; Lopinavir; Mutation; Nelfinavir; Oligopeptides; Organophosphates; Polymorphism, Genetic; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides | 2010 |
Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Cohort Studies; Cyclopropanes; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nephrolithiasis; Oligopeptides; Pyridines; Pyrimidinones; Retrospective Studies; Ritonavir; Sulfonamides | 2011 |
Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes.
Topics: Adipocytes; Animals; Atazanavir Sulfate; Cell Differentiation; Cells, Cultured; Darunavir; HIV Protease Inhibitors; Humans; Insulin Resistance; Lipolysis; Lopinavir; Mice; Mitochondria; Oligopeptides; Pyridines; Reactive Oxygen Species; Ritonavir; Sulfonamides | 2012 |
Structural and thermodynamic basis of amprenavir/darunavir and atazanavir resistance in HIV-1 protease with mutations at residue 50.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Crystallography, X-Ray; Darunavir; Drug Resistance, Viral; Furans; HIV Protease; HIV-1; Humans; Kinetics; Models, Molecular; Mutant Proteins; Mutation, Missense; Oligopeptides; Point Mutation; Protein Binding; Protein Conformation; Pyridines; Sulfonamides; Thermodynamics | 2013 |
GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
Topics: Amino Acid Sequence; Atazanavir Sulfate; Binding Sites; Carbamates; Cell Line, Tumor; Darunavir; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Lopinavir; Molecular Docking Simulation; Molecular Sequence Data; Oligopeptides; Protein Binding; Pyridines; Ritonavir; Structure-Activity Relationship; Sulfonamides; T-Lymphocytes; Virus Replication | 2013 |
Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.
Topics: Alkynes; Anti-Retroviral Agents; Antidepressive Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Darunavir; Drug Interactions; Humans; Models, Biological; Oligopeptides; Pyridines; Ritonavir; Sulfonamides | 2013 |
High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Chromatography, High Pressure Liquid; Cross-Sectional Studies; Crystallization; Darunavir; Female; HIV Infections; Humans; Male; Microscopy, Polarization; Middle Aged; Oligopeptides; Plasma; Pyridines; Sulfonamides; Urine; Young Adult | 2013 |
Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Coinfection; Cyclopropanes; Darunavir; Female; Follow-Up Studies; Hepatitis C; HIV Infections; Humans; Liver; Male; Nevirapine; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2013 |
Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance.
Topics: Atazanavir Sulfate; CD4-Positive T-Lymphocytes; Darunavir; Dose-Response Relationship, Drug; Drug Resistance, Viral; env Gene Products, Human Immunodeficiency Virus; HEK293 Cells; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation, Missense; Oligopeptides; Pyridines; Sulfonamides; Virus Internalization | 2013 |
GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.
Topics: Animals; Astrocytes; Atazanavir Sulfate; Blood-Brain Barrier; Carbamates; Cell Line; Darunavir; Drug Resistance, Multiple, Viral; Endothelial Cells; Fluorides; Haplorhini; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hydrophobic and Hydrophilic Interactions; Lopinavir; Models, Biological; Molecular Docking Simulation; Oligopeptides; Pericytes; Pyridines; Rats; Saquinavir; Sulfonamides; T-Lymphocytes; Virus Replication | 2013 |
Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nephrolithiasis; Oligopeptides; Proportional Hazards Models; Pyridines; Retrospective Studies; Ritonavir; Sulfonamides | 2013 |
Impact of darunavir, atazanavir and lopinavir boosted with ritonavir on cultured human endothelial cells: beneficial effect of pravastatin.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cells, Cultured; Cellular Senescence; Darunavir; Drug Synergism; Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lopinavir; Nitric Oxide; Oligopeptides; Oxidative Stress; Pravastatin; Pyridines; Ritonavir; Sulfonamides | 2014 |
Validation of simultaneous quantitative method of HIV protease inhibitors atazanavir, darunavir and ritonavir in human plasma by UPLC-MS/MS.
Topics: Atazanavir Sulfate; Darunavir; HIV Protease Inhibitors; Humans; Oligopeptides; Plasma; Pyridines; Ritonavir; Sulfonamides | 2014 |
Quantification of cell-associated atazanavir, darunavir, lopinavir, ritonavir, and efavirenz concentrations in human mononuclear cell extracts.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Cell Extracts; Chromatography, Liquid; Cyclopropanes; Darunavir; Humans; Leukocytes, Mononuclear; Lopinavir; Mass Spectrometry; Oligopeptides; Pyridines; Ritonavir; Sulfonamides | 2014 |
Natural polymorphisms and unusual mutations in HIV-1 protease with potential antiretroviral resistance: a bioinformatic analysis.
Topics: Atazanavir Sulfate; Base Sequence; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Molecular Docking Simulation; Molecular Sequence Data; Mutation; Oligopeptides; Phenotype; Polymorphism, Genetic; Pyridines; Pyrones; Sulfonamides | 2014 |
Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticles.
Topics: Adenine; Animals; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Delayed-Action Preparations; Drug Combinations; Drug Delivery Systems; Humans; Hydrogen-Ion Concentration; Lipids; Macaca nemestrina; Oligopeptides; Organophosphonates; Pyridines; Sulfonamides; Tenofovir | 2014 |
[HIV infection. Compatibility of recent protease inhibitors in direct comparison - the advantage of DRV].
Topics: Atazanavir Sulfate; Clinical Trials as Topic; Darunavir; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Pyridines; Sulfonamides; Viral Load | 2014 |
Improved serum cholesterol in paediatric patients switched from suppressive lopinavir-based therapy to boosted darunavir or atazanavir: an 18-month retrospective study.
Topics: Adolescent; Analysis of Variance; Anti-HIV Agents; Atazanavir Sulfate; Child; Cholesterol; Darunavir; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Oligopeptides; Pyridines; Retrospective Studies; Sulfonamides | 2014 |
Safety of darunavir and atazanavir in HIV-infected children in Europe and Thailand.
Topics: Adolescent; Anti-HIV Agents; Atazanavir Sulfate; Child; Cohort Studies; Darunavir; Europe; Female; HIV Infections; Humans; Male; Thailand | 2016 |
Persistence, adherence, and all-cause healthcare costs in atazanavir- and darunavir-treated patients with human immunodeficiency virus in a real-world setting.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Drug Therapy, Combination; Female; Health Expenditures; Health Services; HIV Infections; Humans; Male; Medicaid; Medication Adherence; Middle Aged; Models, Econometric; Propensity Score; Retrospective Studies; Ritonavir; Socioeconomic Factors; United States | 2016 |
HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.
Topics: Atazanavir Sulfate; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Genotyping Techniques; HIV Infections; HIV-1; Humans; Lopinavir; Mutation; Point-of-Care Systems; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure | 2015 |
Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir | 2016 |
Antileishmanial activity of antiretroviral drugs combined with miltefosine.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Antiprotozoal Agents; Atazanavir Sulfate; Benzoxazines; Coinfection; Cyclopropanes; Darunavir; Delavirdine; Drug Therapy, Combination; HIV Infections; Humans; Leishmania infantum; Leishmaniasis, Visceral; Macrophages; Male; Mice, Inbred BALB C; Nevirapine; Phosphorylcholine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Tenofovir | 2016 |
Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
Topics: Adult; Anti-HIV Agents; Antigens, CD; Atazanavir Sulfate; Darunavir; Female; HIV Infections; Humans; Immunophenotyping; Male; Prospective Studies; Raltegravir Potassium; T-Lymphocyte Subsets | 2016 |
Impact of protease inhibitors on the evolution of urinary markers: Subanalyses from an observational cross-sectional study.
Topics: Acute Kidney Injury; Adult; Albuminuria; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biomarkers; Cross-Sectional Studies; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Proteinuria; Ritonavir | 2016 |
Increase in international normalized ratio after switching from atazanavir/ritonavir to darunavir/cobicistat in a patient on warfarin: boosters are not always equal.
Topics: Aged; Anti-HIV Agents; Anticoagulants; Atazanavir Sulfate; Blood Chemical Analysis; Cobicistat; Darunavir; Drug Interactions; HIV Infections; Humans; International Normalized Ratio; Male; Ritonavir; Warfarin | 2017 |
Wide variation in susceptibility of transmitted/founder HIV-1 subtype C Isolates to protease inhibitors and association with in vitro replication efficiency.
Topics: Atazanavir Sulfate; Darunavir; DNA Replication; Drug Resistance, Viral; gag Gene Products, Human Immunodeficiency Virus; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Virus Replication; Zambia | 2016 |
Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?
Topics: Anti-HIV Agents; Atazanavir Sulfate; Biological Availability; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Dosage Calculations; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Rilpivirine; Viral Load | 2017 |
From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults.
Topics: Adolescent; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cross-Sectional Studies; Darunavir; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Mutation; Prospective Studies; Uganda; Young Adult | 2016 |
Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir.
Topics: Adult; Atazanavir Sulfate; Cohort Studies; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Lopinavir; Male; Middle Aged; Treatment Outcome; United Kingdom | 2017 |
Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure.
Topics: Adult; Atazanavir Sulfate; Darunavir; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Medication Adherence; Middle Aged; Registries; Regression Analysis; Retrospective Studies; Ritonavir; RNA, Viral; Treatment Failure; Viral Load | 2017 |
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; British Columbia; Canada; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Ritonavir | 2017 |
Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Biomarkers; Brachial Artery; Cardiovascular Diseases; Carotid Intima-Media Thickness; CD4 Lymphocyte Count; Chi-Square Distribution; Cyclopropanes; Darunavir; Endothelium, Vascular; Female; HIV Infections; Humans; Inflammation Mediators; Italy; Lipids; Longitudinal Studies; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Predictive Value of Tests; Risk Factors; Ritonavir; Time Factors; Treatment Outcome; Vasodilation | 2017 |
Antiretroviral unbound concentration during pregnancy: piece of interest in the puzzle?
Topics: Atazanavir Sulfate; Blood Proteins; Darunavir; Dose-Response Relationship, Drug; Female; Hepatocytes; HIV Infections; HIV Protease Inhibitors; Humans; Pregnancy; Protein Binding | 2017 |
Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS Dementia Complex; AIDS-Related Opportunistic Infections; Alkynes; Americas; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Cyclopropanes; Darunavir; Europe; Female; HIV Protease Inhibitors; Humans; Leukoencephalopathy, Progressive Multifocal; Lopinavir; Male; Meningitis, Cryptococcal; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Toxoplasmosis | 2018 |
No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; pol Gene Products, Human Immunodeficiency Virus; Ritonavir; Viral Load | 2018 |
Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.
Topics: Adolescent; Atazanavir Sulfate; Child; Cohort Studies; Darunavir; Drug Therapy, Combination; Dyslipidemias; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipids; Longitudinal Studies; Male; Ritonavir; Viral Load; Young Adult | 2018 |
Atazanavir and darunavir in pregnant women with HIV: evaluation of laboratory and clinical outcomes from an observational national study.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Cholesterol; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Infant; Infant, Newborn; Male; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Treatment Outcome; Triglycerides; Viral Load | 2018 |
The relevance of drug-drug interactions in clinical practice: the case of concomitant boosted protease inhibitors plus alpha-1 blocker administration.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Atazanavir Sulfate; Cobicistat; Darunavir; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Retrospective Studies; Ritonavir | 2018 |
Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.
Topics: Adult; Atazanavir Sulfate; Australia; Cardiovascular Diseases; Darunavir; Drug Therapy, Combination; Europe; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Male; Middle Aged; Prospective Studies; Treatment Outcome; United States | 2018 |
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4-CD8 Ratio; Cohort Studies; Darunavir; Dideoxynucleosides; Female; HIV Infections; Humans; Inflammation; Italy; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2018 |
Inhibition of the precursor and mature forms of HIV-1 protease as a tool for drug evaluation.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cell Line; Darunavir; Flow Cytometry; Fluorescence Resonance Energy Transfer; Fluorescent Dyes; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Protein Precursors; Proteolysis | 2018 |
Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Biomarkers; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Inflammation; Male; Middle Aged; Prospective Studies; Ritonavir | 2018 |
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients - evidence from a large observational cohort.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Darunavir; HIV; HIV Infections; Humans; Lamivudine; Ritonavir | 2019 |
Atazanavir urolithiasis without recent intake of atazanavir.
Topics: Adult; Atazanavir Sulfate; Darunavir; Drug Administration Schedule; Drug Substitution; Hepatitis C; HIV Infections; Humans; Inactivation, Metabolic; Late Onset Disorders; Liver; Male; Time Factors; Urolithiasis | 2019 |
Drug-Drug Interactions Between Antiretrovirals and Carbamazepine/Oxcarbazepine: A Real-Life Investigation.
Topics: Adult; Anti-Retroviral Agents; Anticonvulsants; Atazanavir Sulfate; Carbamazepine; Darunavir; Drug Interactions; Drug Monitoring; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Oxazines; Oxcarbazepine; Piperazines; Pyridones | 2020 |
Live Attenuated Vaccine With a Stabilized Mutation and Gene Deletion for Prevention of Respiratory Syncytial Virus Disease in Young Children.
Topics: Atazanavir Sulfate; Case-Control Studies; Child; Child, Preschool; Darunavir; Gene Deletion; HIV; HIV Infections; Humans; Myocardial Infarction; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses | 2020 |
Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV.
Topics: Adult; Atazanavir Sulfate; Case-Control Studies; Cohort Studies; Darunavir; Databases, Factual; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Myocardial Infarction; Risk Factors; Treatment Outcome | 2020 |
Darunavir and Cardiovascular Risk: Evaluating the Data to Inform Clinical Care.
Topics: Atazanavir Sulfate; Cardiovascular Diseases; Case-Control Studies; Darunavir; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Myocardial Infarction; Risk Factors | 2020 |
Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biopsy; CD4-Positive T-Lymphocytes; Cross-Sectional Studies; Darunavir; Female; Gastrointestinal Tract; HIV Infections; HIV-1; Humans; Ileum; Lymph Nodes; Male; Raltegravir Potassium; Real-Time Polymerase Chain Reaction; San Francisco; Virus Replication | 2020 |
Effects of atazanavir, darunavir, and raltegravir on fat and muscle among persons living with HIV.
Topics: Adipose Tissue; Adult; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Hospitals, Teaching; Humans; Italy; Male; Middle Aged; Muscles; Raltegravir Potassium; Retrospective Studies; Viral Load | 2020 |
Association Between Atazanavir-Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIV.
Topics: Atazanavir Sulfate; Bilirubin; Cardiovascular Diseases; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Ischemic Stroke; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Retrospective Studies; Time Factors | 2020 |
Unveiling the basis of antiretroviral therapy-induced osteopenia: the effects of Dolutegravir, Darunavir and Atazanavir on osteogenesis.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Bone Diseases, Metabolic; Darunavir; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Osteogenesis; Oxazines; Piperazines; Pyridones | 2021 |
Higher plasma drug levels in elderly people living with HIV treated with darunavir.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Case-Control Studies; Cross-Sectional Studies; Cyclopropanes; Darunavir; Drug Interactions; HIV Infections; Humans; Male; Middle Aged; Plasma; Sweden | 2021 |
Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19?
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Atazanavir Sulfate; COVID-19 Drug Treatment; Darunavir; Drug Combinations; Drug Therapy, Combination; Early Medical Intervention; Emtricitabine; Humans; Lamivudine; Lopinavir; Molecular Docking Simulation; Nucleosides; Protease Inhibitors; Ritonavir; SARS-CoV-2 | 2021 |
Changes in lipidomic profile by anti-retroviral treatment regimen: An ACTG 5257 ancillary study.
Topics: Adult; Anti-Retroviral Agents; Atazanavir Sulfate; Chi-Square Distribution; Darunavir; Female; HIV Infections; Humans; Lipidomics; Lipids; Male; Mass Spectrometry; Middle Aged; Plasma; Raltegravir Potassium; Tenofovir | 2021 |
Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Cohort Studies; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Oxazines; Piperazines; Pregnancy; Premature Birth; Pyridones; Quinolones; Raltegravir Potassium; Rilpivirine; Ritonavir; United States | 2022 |
Antiretroviral protease inhibitors induce features of cellular senescence that are reversible upon drug removal.
Topics: Aging, Premature; Animals; Anti-HIV Agents; Atazanavir Sulfate; Cellular Senescence; Darunavir; HIV Infections; HIV Protease Inhibitors; Mice; Ritonavir | 2023 |
Evaluation of COVID-19 protease and HIV inhibitors interactions.
Topics: Antiviral Agents; Atazanavir Sulfate; COVID-19; Darunavir; Humans; Lopinavir; Molecular Docking Simulation; Peptide Hydrolases; Protease Inhibitors | 2022 |
Mechanistic in vitro studies indicate that the clinical drug-drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3.
Topics: Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily G, Member 2; Darunavir; Drug Interactions; Lopinavir; Neoplasm Proteins; Protease Inhibitors; Ritonavir; Rosuvastatin Calcium | 2023 |